These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. Liu T; Wang Z; Guo P; Ding N Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115 [TBL] [Abstract][Full Text] [Related]
24. Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A. Aranda S; Alvarez M; Turró S; Laguna A; de la Luna S Mol Cell Biol; 2008 Oct; 28(19):5899-911. PubMed ID: 18678649 [TBL] [Abstract][Full Text] [Related]
25. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding. Zhu J; Balan V; Bronisz A; Balan K; Sun H; Leicht DT; Luo Z; Qin J; Avruch J; Tzivion G Mol Biol Cell; 2005 Oct; 16(10):4733-44. PubMed ID: 16093354 [TBL] [Abstract][Full Text] [Related]
26. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
27. Rit contributes to nerve growth factor-induced neuronal differentiation via activation of B-Raf-extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades. Shi GX; Andres DA Mol Cell Biol; 2005 Jan; 25(2):830-46. PubMed ID: 15632082 [TBL] [Abstract][Full Text] [Related]
28. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling. Siljamäki E; Abankwa D Mol Cell Biol; 2016 Oct; 36(20):2612-25. PubMed ID: 27503857 [TBL] [Abstract][Full Text] [Related]
30. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719 [TBL] [Abstract][Full Text] [Related]
31. Regulation and role of Raf-1/B-Raf heterodimerization. Rushworth LK; Hindley AD; O'Neill E; Kolch W Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002 [TBL] [Abstract][Full Text] [Related]
32. Sprouty2 and Spred1-2 proteins inhibit the activation of the ERK pathway elicited by cyclopentenone prostanoids. García-Domínguez CA; Martínez N; Gragera T; Pérez-Rodríguez A; Retana D; León G; Sánchez A; Oliva JL; Pérez-Sala D; Rojas JM PLoS One; 2011 Feb; 6(2):e16787. PubMed ID: 21364986 [TBL] [Abstract][Full Text] [Related]
33. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623 [TBL] [Abstract][Full Text] [Related]
34. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530 [TBL] [Abstract][Full Text] [Related]
35. A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Dhillon AS; Meikle S; Peyssonnaux C; Grindlay J; Kaiser C; Steen H; Shaw PE; Mischak H; Eychène A; Kolch W Mol Cell Biol; 2003 Mar; 23(6):1983-93. PubMed ID: 12612072 [TBL] [Abstract][Full Text] [Related]
36. RAF protein-serine/threonine kinases: structure and regulation. Roskoski R Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547 [TBL] [Abstract][Full Text] [Related]
37. Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction. Martínez N; García-Domínguez CA; Domingo B; Oliva JL; Zarich N; Sánchez A; Gutiérrez-Eisman S; Llopis J; Rojas JM Cell Signal; 2007 Nov; 19(11):2277-85. PubMed ID: 17689925 [TBL] [Abstract][Full Text] [Related]
38. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508 [TBL] [Abstract][Full Text] [Related]
39. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246 [TBL] [Abstract][Full Text] [Related]
40. Differential Effects of Variations at Codon 106 on Sprouty2 Functions in Lung Cancer-Derived Cells. Kral R; Doriguzzi A; Mayer CE; Krenbek D; Setinek U; Sutterlüty-Fall H J Cell Biochem; 2016 Aug; 117(8):1822-32. PubMed ID: 26727965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]